SCHEMBL830379

SCHEMBL830379

COc1ccc(CS(=O)(=O)c2cc3ccc(OC)cc3oc2=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.66
CA12 O43570 5/20 0.66
CA1 P00915 4/20 0.66
CA9 Q16790 4/20 0.66
GLA P06280 3/20 0.60
GAA P10253 3/20 0.60
KDM4E B2RXH2 3/20 0.60
PKM P14618 1/20 0.60
SIRT2 Q8IXJ6 1/20 0.58
RXFP1 Q9HBX9 1/20 0.53
GPR55 Q9Y2T6 1/20 0.52
POLB P06746 1/20 0.52
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
KMT2A Q03164 2/20 0.50
MAOB P27338 2/20 0.50
SLC16A3 O15427 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831128 0.90 MIF (0.58) CA2CA12CA1CA9GLA
SCHEMBL830092 0.89 GAA (0.53) CA2CA12CA1CA9GLA
SCHEMBL829057 0.87 CA2 (0.72) CA2CA12CA1CA9GLA
SCHEMBL830002 0.83 MAOB (0.58) CA2CA12CA1CA9GLA
SCHEMBL830208 0.83 POLB (0.58) CA2CA12CA1CA9GLA
SCHEMBL830580 0.83 CA12 (0.52) CA2CA12CA1CA9GLA
SCHEMBL831375 0.82 KDM4E (0.80) CA2CA12CA1CA9GLA
SCHEMBL829273 0.81 CNR2 (0.52) CA2CA12CA1CA9GLA
SCHEMBL21033654 0.80 KDM4E (0.85) CA2CA12CA1CA9GLA
SCHEMBL830984 0.78 CA2 (0.57) CA2CA12CA1CA9GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US claimed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP claimed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 CA2 2552/4885CA12 2448/4885CA1 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.